Every so often, the market hands investors a gift. And they're afraid to unwrap it.

When a world-class business goes on sale, most folks grow suspicious. They convince themselves there must be a catch, and they sit on the sidelines.

A few years later, they look back and kick themselves for missing an obvious setup. They promise they won't hesitate next time.

That is, until the next gift arrives.

And it always comes again. Even the greatest companies – elite businesses that compound for decades – sometimes hit uncomfortable pullbacks.

In 2018, for example, Walmart (WMT) dropped 25%. And starting later that year, Apple (AAPL) crashed nearly 40%.

Both were incredible buying opportunities. Both look obvious today.

So why is pulling the trigger so hard in real time?

Well, this hesitation can be best explained by a cognitive bias known as hyperbolic discounting.

Imagine someone offered you a choice... You can receive $2,000 today or $2,200 two months from now.

Which would you take?

Ask most folks, and they'd grab the $2,000 today. The immediate reward feels tangible, safe, and satisfying. The future reward, even though it's only two months out, feels distant and uncertain.

Now, suppose that same person offered you $2,000 in 12 months or $2,200 in 14 months.

Suddenly, waiting those extra two months becomes easy. You gladly choose to wait for the additional $200. After all, what's the difference between 12 months and 14 months?

Notice that in both scenarios, the extra reward ($200) and the time delay (two months) are identical. Yet our brains react completely differently depending on how close the choice is to the present.

This mental paradox reveals our tendency to place far more weight on what's happening today than on what might happen tomorrow.

The human mind struggles to evaluate time on a straight line. Our brains evolved in an environment where immediate survival was everything. Catching dinner today mattered infinitely more than planning for a year down the road.

In investing, hyperbolic discounting is one reason why even smart, rational investors consistently miss the stock market's greatest buying opportunities.

Walmart, for example, was in bear market territory back in 2018 because of fears over Amazon stealing market share. Investors panicked over how much Walmart would have to spend to compete online, speculating it would destroy profit margins. Take a look...

Those worries were completely overblown. The underlying business remained formidable. Walmart held huge purchasing power, a vast store network, and a trusted brand.

Plus, investors failed to realize that Walmart's massive footprint was actually a secret weapon. Its network of retail stores created a ready-made fulfillment system that Amazon would have to spend tens of billions of dollars to replicate. Online sales quickly became a major growth driver for the company.

Walmart has returned more than 350% since its 2018 lows, even counting its latest drawdown. That "big" drop barely registers.

There's also Apple, which fell nearly 40% from late 2018 into early 2019.

The company cut revenue guidance, mainly because of a brief slowdown in China. Analysts also worried that the iPhone had become too expensive and that smartphone growth was dead. So the market panicked and sold off the stock...

But Apple was still Apple. Fast-forward to today, and almost everyone is still glued to their iPhones.

At the end of 2018, roughly 900 million people around the world had iPhones. Those customers created recurring revenue opportunities through the App Store, iCloud, Apple Music, and other services... even when they weren't replacing their handsets. Apple's services revenue now brings in more than $100 billion a year.

And Apple has returned more than 900% since its 2019 lows, making that 39% drop look like nothing...

Even the best stocks experience significant drawdowns. It's your job to buy them when that happens.

Instead of stepping back and looking at each company through a long-term telescope, though, hyperbolic discounting forces investors to look through a short-term microscope.

Your brain fixates entirely on the immediate present...

What if the stock drops another 10% next week?

The next two quarters of earnings are going to be ugly. I'll just wait until things calm down.

When a great company hits a rough patch, investors struggle to separate temporary setbacks from permanent damage. Slowing sales, disappointing earnings, or a brief shift in consumer spending quickly overshadow years of market dominance. Suddenly, a business that once seemed untouchable is treated as if its best days are behind it.

But some of the market's most attractive opportunities emerge precisely when investors lose sight of the long term.

Now, not every struggling blue chip is automatically a bargain. Sometimes a sell-off reflects genuine, lasting deterioration. The key is distinguishing between a business whose competitive edge is eroding and one that has simply fallen out of favor for a few quarters.

That distinction brings us to a blue-chip stock that's currently experiencing one of its largest drawdowns in recent memory...

We're talking about a legendary compounder that has delivered an average annual return of 14.3% since 1980.

The company is working through some short-term issues. And investors have lost sight of its long-term competitive advantages.

But this stock is a screaming buy at today's prices. Don't let hyperbolic discounting stop you from taking advantage of this rare opportunity to build your long-term wealth.

Current Retirement Millionaire subscribers can read our buy recommendation here.

If you aren't yet a Retirement Millionaire subscriber but would like to learn more, click here.

What We're Reading...

Here's to our health, wealth, and a great retirement,

Dr. David Eifrig and the Health & Wealth Bulletin Research Team
October 21, 2026

Recent Articles

View Full Archives
Subscribe to Health & Wealth Bulletin for FREE
Get the Health & Wealth Bulletin delivered straight to your inbox.
About Health & Wealth Bulletin

Here at Health & Wealth Bulletin, our manifesto is to provide a guide for living well – at a good price and on your own terms.

We've told folks the secret to life-changing income in retirement, the exit plan that every investor needs, and the key to beating the market. And our team has been on the leading edge of reporting new discoveries like immunotherapy, the dangers of BPA, the truth about cholesterol, and more.

You see, huge corporate interests and corrupt government institutions would rather people didn't know about many of these concepts... The more ignorant the people are, the better for the government and corporate interests. This keeps folks dependent... and the "nanny state" alive. That's why we spend our days uncovering the truth and sharing it with readers.

Health & Wealth Bulletin is your free guidebook to intriguing health and wealth ideas. It's all about living the best life possible.

About the Editor
Dr. David "Doc" Eifrig
Dr. David "Doc" Eifrig
Editor

Dr. David "Doc" Eifrig has one of the most remarkable resumes of anyone we know in the finance industry. After receiving his Bachelor of Arts degree from Carleton College in Minnesota, he went on to earn a Master of Business Administration degree

from Northwestern University's Kellogg School of Management. There, he graduated on the Dean's List with a double major in finance and international business.

Doc then went to work as an elite derivatives trader at the Goldman Sachs investment bank. He spent a decade on Wall Street with several major institutions, including Chase Manhattan Bank and Yamaichi Securities (then known as the "Goldman Sachs of Japan").

That's when Doc's career took an unconventional turn. Sick of the greed and hypocrisy on Wall Street, he quit his Senior Vice President position to become a doctor. He graduated from Columbia University's postbaccalaureate premedical program and eventually earned his Medical Doctor degree with clinical honors from the University of North Carolina at Chapel Hill. While in medical school, he was elected president of his class and admitted to the Order of the Golden Fleece – the highest honor awarded at the university.

Doc also completed a research fellowship in molecular genetics at Duke University and became a board-eligible eye surgeon. Along the way, he has been published in scientific journals and helped start a small biotechnology company, Mirus Bio, which was sold to Roche for $125 million in 2008.

However, frustrated by Big Medicine's many conflicts, Doc began to look for ways to talk directly with individuals. He wanted to use his background to show them how to take control of their health and wealth. In 2008, Doc joined Stansberry Research and launched his publication, Retirement Millionaire. He has gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams. Doc's Income Intelligence seeks out income-producing investments to maximize returns. Prosperity Investor helps investors unlock massive potential gains in health care investing. Every Monday through Friday, Doc shares his views on the latest in the financial and health industries – and tips on how to improve your own life – in Health & Wealth Bulletin.

Doc has also authored five books with four-star ratings (or better) on Amazon. In his spare time, he has run three marathons and several triathlons. He owns and produces his own wine (Eifrig Cellars) in northern Sonoma County, California. Doc is also the CEO of MarketWise, Stansberry Research's parent company.

Back to Top